Efficacy and safety of teplizumab in Japanese participants with Stage 2 type 1 diabetes

Trial Identifier: ACT18487
Sponsor: Sanofi
Start Date: July 2025
Primary Completion Date: March 2028
Study Completion Date: March 2028
Condition: Diabetes: Type 1

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
JAPAN, Chiba Ichikawa, Chiba, JAPAN, 272-0827
JAPAN, Fukuoka Fukuoka, JAPAN, 812-0025
JAPAN, Hokkaido Sapporo, Hokkaido, JAPAN, 060-8543
JAPAN, Hyogo Kobe, Hyogo, JAPAN, 650-0017
JAPAN, Iwate Yahaba, Iwate, JAPAN, 028-3695
JAPAN, Kanagawa Yokohama, Kanagawa, JAPAN, 222-0036
JAPAN, Kyoto Kyoto, JAPAN, 606-8507
JAPAN, Osaka Osaka, JAPAN, 545-8586
JAPAN, Saitama Iruma, Saitama, JAPAN, 350-0495
JAPAN, Tokyo Tokyo, JAPAN, 101-8309
JAPAN, Yamanashi Chuo, Yamanashi, JAPAN, 409-3898